Teva Pharmaceutical Industries Limited (TEVA) Holdings Trimmed by Paulson & CO. Inc.

Paulson & CO. Inc. lessened its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 38.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,744,000 shares of the company’s stock after selling 4,253,300 shares during the quarter. Teva Pharmaceutical Industries Limited accounts for 3.0% of Paulson & CO. Inc.’s portfolio, making the stock its 12th largest position. Paulson & CO. Inc. owned 0.66% of Teva Pharmaceutical Industries Limited worth $224,036,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of TEVA. American International Group Inc. acquired a new stake in Teva Pharmaceutical Industries Limited during the 1st quarter valued at approximately $523,000. Cornerstone Capital Management Holdings LLC. acquired a new stake in Teva Pharmaceutical Industries Limited during the 1st quarter valued at approximately $596,000. Teachers Advisors LLC grew its stake in Teva Pharmaceutical Industries Limited by 6.1% during the 1st quarter. Teachers Advisors LLC now owns 642,314 shares of the company’s stock valued at $20,612,000 after purchasing an additional 36,900 shares in the last quarter. Legal & General Group Plc grew its stake in Teva Pharmaceutical Industries Limited by 5.8% during the 1st quarter. Legal & General Group Plc now owns 590,102 shares of the company’s stock valued at $18,936,000 after purchasing an additional 32,515 shares in the last quarter. Finally, Thrivent Financial For Lutherans grew its stake in Teva Pharmaceutical Industries Limited by 28.2% during the 1st quarter. Thrivent Financial For Lutherans now owns 142,420 shares of the company’s stock valued at $4,571,000 after purchasing an additional 31,300 shares in the last quarter. Hedge funds and other institutional investors own 56.76% of the company’s stock.

A number of research analysts have commented on the company. Vetr downgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 target price on the stock. in a report on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Thursday, June 22nd. BidaskClub downgraded Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 16th. Citigroup Inc. downgraded Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $32.00 to $19.00 in a report on Wednesday, August 16th. Finally, Maxim Group reaffirmed a “hold” rating and set a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, July 13th. Five research analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $27.63.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 0.14% during trading on Tuesday, hitting $14.69. The company had a trading volume of 5,048,425 shares. Teva Pharmaceutical Industries Limited has a 12-month low of $14.30 and a 12-month high of $44.42. The firm has a 50 day moving average of $16.73 and a 200 day moving average of $26.05. The stock’s market cap is $14.93 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the previous year, the firm posted $1.25 EPS. The business’s revenue was up 12.9% on a year-over-year basis. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post $4.24 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Holdings Trimmed by Paulson & CO. Inc.” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.com-unik.info/2017/10/17/teva-pharmaceutical-industries-limited-teva-holdings-trimmed-by-paulson-co-inc.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit